BREAST CANCER HER2-POSITIVE Clinical Trials

42 clinical trials for BREAST CANCER HER2-POSITIVE across international registries, including 28 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A TWO-PART, SEAMLESS, MULTICENTER, RANDOMIZED, OPEN-LABEL, ADAPTIVE PHASE II/III STUDY OF THE BLOOD-BRAIN BARRIER PENETRANT RO7771950 VERSUS TUCATINIB, BOTH IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE, IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER, WITH OR WITHOUT CENTRAL NERVOUS SYSTEM METASTASES — RECRUITING · PHASE2
• A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZANIDATAMAB IN COMBINATION WITH PHYSICIAN¿S CHOICE CHEMOTHERAPY COMPARED TO TRASTUZUMAB IN COMBINATION WITH PHYSICIAN'S CHOICE CHEMOTHERAPY FOR THE TREATMENT OF PARTICIPANTS WITH METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE PROGRESSED ON, OR ARE INTOLERANT TO, PREVIOUS TRASTUZUMAB DERUXTECAN TREATMENT — RECRUITING · PHASE3
• A PHASE 1B/2 OPEN-LABEL STUDY OF DISITAMAB VEDOTIN MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS — RECRUITING · PHASE1
• A PHASE 3, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY OF DB-1303 VERSUS INVESTIGATOR¿S CHOICE CHEMOTHERAPY IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-LOW, HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER PATIENTS WHOSE DISEASE HAS PROGRESSED ON ENDOCRINE THERAPY (ET) (DYNASTY-BREAST02) — RECRUITING · PHASE3
• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO® VERSUS PLACEBO IN COMBINATION WITH PHESGO® AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA-MUTATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER — RECRUITING · PHASE3
• DE-ESCALATION OF ADJUVANT CHEMOTHERAPY IN HER2-POSITIVE, ESTROGEN RECEPTOR-NEGATIVE, NODE-NEGATIVE EARLY BREAST CANCER PATIENTS WHO ACHIEVED PATHOLOGICAL COMPLETE RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY AND DUAL HER2 BLOCKADE-DECRESCENDO — RECRUITING
• A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS ADMINISTRATION IN PARTICIPANTS WITH EARLY OR LOCALLY ADVANCED/ INFLAMMATORY HER2- POSITIVE BREAST CANCER — RECRUITING · PHASE3
• THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2+ BREAST CANCER (HER2CLIMB-05) — RECRUITING · PHASE3
• A GLOBAL, PHASE 2 STUDY OF ARX788 IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS WHOSE DISEASE IS RESISTANT OR REFRACTORY TO T-DM1, AND/OR T-DXD, AND/OR TUCATINIB-CONTAINING REGIMENS — RECRUITING · PHASE2
• AN OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HER2-POSITIVE BREAST CANCER (DESTINY-BREAST12)¿ — RECRUITING · PHASE3
• PHASE III STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) WITH OR WITHOUT PERTUZUMAB VERSUS TAXANE, TRASTUZUMAB AND PERTUZUMAB IN HER2-POSITIVE, FIRST-LINE METASTATIC BREAST CANCER (DESTINY-BREAST09) — RECRUITING · PHASE3
• A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY (DESTINY BREAST05)¿ — RECRUITING · PHASE3
• A PHASE 1B/2 MULTICENTRE, OPEN-LABEL, MODULAR, DOSE-FINDING AND DOSE EXPANSION STUDY TO EXPLORE THE SAFETY, TOLERABILITY, AND ANTI-TUMOUR ACTIVITY OF TRASTUZUMAB DERUXTECAN (T DXD) IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER (DESTINY-BREAST07) — RECRUITING · PHASE1
• A MULTICENTER, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, DOSIMETRY, AND PRELIMINARY EFFICACY OF THE HER2-DIRECTED RADIOLIGAND CAM-H2 IN PATIENTS WITH ADVANCED/METASTATIC HER2-POSITIVE BREAST, GASTRIC, GASTROESOPHAGEAL JUNCTION, AND OTHER HER2-POSITIVE SOLID TUMORS — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF PACLITAXEL/TRASTUZUMAB/PERTUZUMAB WITH ATEZOLIZUMAB OR PLACEBO IN FIRST-LINE HER2 POSITIVE METASTATIC BREAST CANCER — RECRUITING · PHASE3
• PHASE 2A STUDY OF ZW25 IN COMBINATION WITH PALBOCICLIB PLUS FULVESTRANT — RECRUITING · PHASE2
• A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER — RECRUITING · PHASE3
• A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER — RECRUITING · PHASE3
• A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS WHO ARE RESISTANT OR REFRACTORY TO T-DM1 — RECRUITING · PHASE2
• A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY — RECRUITING · PHASE2
• MONARCHER: A PHASE 2, RANDOMIZED, MULTICENTER, 3-ARM, OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS TRASTUZUMAB WITH OR WITHOUT FULVESTRANT TO STANDARD-OF-CARE CHEMOTHERAPY OF PHYSICIAN'S CHOICE PLUS TRASTUZUMAB IN WOMEN WITH HR+, HER2+ LOCALLY ADVANCED OR METASTATIC BREAST CANCER. — RECRUITING · PHASE2
• A PHASE 1B PHARMACODYNAMIC STUDY OF DURVALUMAB (MEDI4736) IN PATIENTS WITH HER-2 POSITIVE METATSTATIC BREAST CANCER (MBC) RECEIVING TRASTUMUZAB — RECRUITING · PHASE1
• A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN SC IN COMBINATION WITH PERJETA AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY RECURRENT) — RECRUITING
• A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY OF MM-302 PLUS TRASTUZUMAB VS. CHEMOTHERAPY OF PHYSICIAN'S CHOICE PLUS TRASTUZUMAB IN ANTHRACYCLINE NAIVE PATIENTS WITH LOCALLY ADVANCED/METASTATIC HER2-POSITIVE BREAST CANCER — RECRUITING
• PHASE III STUDY EVALUATING PALBOCICLIB (PD-0332991), A CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITOR IN PATIENTS WITH HORMONE-RECEPTOR-POSITIVE, HER2-NORMAL PRIMARY BREAST CANCER WITH HIGH RELAPSE RISK AFTER NEOADJUVANT CHEMOTHERAPY — RECRUITING · PHASE3
• A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE III NEOADJUVANT STUDY EVALUATING TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB COMPARED WITH CHEMOTHERAPY PLUS TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH HER-2 POSITIVE BREAST CANCER — RECRUITING · PHASE3
• A PHASE 1B / 2, MULTICENTER, MULTI ARM STUDY OF EVORPACEPT IN COMBINATION WITH ANTI-CANCER THERAPIES IN ADVANCED / METASTATIC MALIGNANCIES / A SINGLE-ARM PHASE 2 MULTICENTER STUDY OF EVORPACEPT IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC HER2-POSITIVE BREAST CANCER — NOT_YET_RECRUITING · PHASE2
• A PHASE IB, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF THE COMBINATION OF RUNIMOTAMAB, TRASTUZUMAB, AND RO7122290 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER — NOT_YET_RECRUITING · PHASE1
• RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TUCATINLB OR PLACEBO IN COMBINATION WITH ADO-TRASTUZUMAB EMTANSINE (T-DML) FOR SUBJECTS WITH UNRESECTABLE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (HER2CLIMB-02) — COMPLETED · PHASE3
• EPIK-B2: A TWO PART, PHASE III, MULTICENTER, RANDOMIZED (1:1), DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER WITH A PIK3CA MUTATION — COMPLETED · PHASE3
• A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS ADO-TRASTUZUMAB EMTANSINE (T-DM1) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH TRASTUZUMAB AND TAXANE — COMPLETED · PHASE3
• A PHASE 1B STUDY OF POZIOTINIB IN COMBINATION WITH T DM1 IN WOMEN WITH ADVANCED OR METASTATIC HER2 POSITIVE BREAST CANCER — NOT_YET_RECRUITING · PHASE1
• A MULTI-CENTRE, OPEN-LABEL, RANDOMIZED CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF THE ANTIBODY-DRUG CONJUGATE SYD985 TO PHYSICIAN'S CHOICE IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER — COMPLETED
• PHASE 2 RANDOMIZED, DOUBLE-BLINDED, CONTROLLED STUDY OF ONT-380 VS. PLACEBO IN COMBINATION WITH CAPECITABINE AND TRASTUZUMAB IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CARCINOMA — COMPLETED · PHASE2
• AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA IN PATIENTS WITH EARLY-STAGE HER2+ BREAST CANCER TREATED WITH NERATINIB AND INTENSIVE LOPERAMIDE PROPHYLAXIS — COMPLETED
• A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT — COMPLETED · PHASE3
• PHASE I MULTICENTER CLINICAL TRIAL EVALUATING THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND DOXORUBICIN IN HER2-POSITIVE METASTATIC BREAST CANCER. — NOT_YET_RECRUITING · PHASE1
• A MULTICENTER, MULTINATIONAL, PHASE II STUDY TO EVALUATE PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND STANDARD NEOADJUVANT ANTHRACYCLINE-BASED CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE. LOCALLY ADVANCED, INFLAMMATORY, OR EARLY-STAGE BREAST CANCER — COMPLETED · PHASE2
• A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER — COMPLETED · PHASE3
• A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2 DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA) — COMPLETED

Refine this search